Littérature scientifique sur le sujet « INTERFERON-GAMMA ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION GVHD »
Créez une référence correcte selon les styles APA, MLA, Chicago, Harvard et plusieurs autres
Sommaire
Consultez les listes thématiques d’articles de revues, de livres, de thèses, de rapports de conférences et d’autres sources académiques sur le sujet « INTERFERON-GAMMA ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION GVHD ».
À côté de chaque source dans la liste de références il y a un bouton « Ajouter à la bibliographie ». Cliquez sur ce bouton, et nous générerons automatiquement la référence bibliographique pour la source choisie selon votre style de citation préféré : APA, MLA, Harvard, Vancouver, Chicago, etc.
Vous pouvez aussi télécharger le texte intégral de la publication scolaire au format pdf et consulter son résumé en ligne lorsque ces informations sont inclues dans les métadonnées.
Articles de revues sur le sujet "INTERFERON-GAMMA ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION GVHD"
Thiele Orberg, Erik, Julius Clemens Fischer, Sascha Göttert, Florian Bassermann et Hendrik Poeck. « Type I Interferon Signaling before Hematopoietic Stem Cell Transplantation Lowers Donor T Cell Activation Via Reduced Allogenicity of Recipient Cells ». Blood 134, Supplement_1 (13 novembre 2019) : 4431. http://dx.doi.org/10.1182/blood-2019-128784.
Texte intégralWu, Yongxia, Corey Mealer, Mohammed Sofi, Linlu Tian, David Bastian, Steven Schutt, Hee-Jin Choi, Chih-Hang Anthony Tang, Chih-Chi Andrew Hu et Xue-Zhong Yu. « STING Negatively Regulates Allogeneic T Cell Responses by Constraining Function of Antigen Presenting Cells ». Journal of Immunology 204, no 1_Supplement (1 mai 2020) : 87.11. http://dx.doi.org/10.4049/jimmunol.204.supp.87.11.
Texte intégralBader, Cameron S., Lei Jin et Robert B. Levy. « STING and transplantation : can targeting this pathway improve outcomes ? » Blood 137, no 14 (8 avril 2021) : 1871–78. http://dx.doi.org/10.1182/blood.2020008911.
Texte intégralAra, Takahide, Daigo Hashimoto, Eiko Hayase, Clara Noizat, Ryo Kikuchi, Yuta Hasegawa, Kana Matsuda et al. « Intestinal goblet cells protect against GVHD after allogeneic stem cell transplantation via Lypd8 ». Science Translational Medicine 12, no 550 (1 juillet 2020) : eaaw0720. http://dx.doi.org/10.1126/scitranslmed.aaw0720.
Texte intégralKaufman, CL, YL Colson, SM Wren, S. Watkins, RL Simmons et ST Ildstad. « Phenotypic characterization of a novel bone marrow-derived cell that facilitates engraftment of allogeneic bone marrow stem cells ». Blood 84, no 8 (15 octobre 1994) : 2436–46. http://dx.doi.org/10.1182/blood.v84.8.2436.2436.
Texte intégralKaufman, CL, YL Colson, SM Wren, S. Watkins, RL Simmons et ST Ildstad. « Phenotypic characterization of a novel bone marrow-derived cell that facilitates engraftment of allogeneic bone marrow stem cells ». Blood 84, no 8 (15 octobre 1994) : 2436–46. http://dx.doi.org/10.1182/blood.v84.8.2436.bloodjournal8482436.
Texte intégralChoi, Jaebok, Edward D. Ziga, Julie Ritchey, Lynne Collins, Julie L. Prior, Matthew L. Cooper, David Piwnica-Worms et John F. DiPersio. « IFNγR signaling mediates alloreactive T-cell trafficking and GVHD ». Blood 120, no 19 (8 novembre 2012) : 4093–103. http://dx.doi.org/10.1182/blood-2012-01-403196.
Texte intégralGöttert, Sascha, Julius Clemens Fischer, Gabriel Eisenkolb, Erik Thiele Orberg, Dirk Busch, Sebastian Jarosch, Ernst Holler et al. « IFN-Gamma Producing Regulatory T Cells Counterbalance T Cell-Mediated Injury to the Intestinal Stem Cell Compartment in Mice and Humans ». Blood 138, Supplement 1 (5 novembre 2021) : 89. http://dx.doi.org/10.1182/blood-2021-152925.
Texte intégralBregni, Marco, Anna Dodero, Jacopo Peccatori, Alessandra Pescarollo, Massimo Bernardi, Isabella Sassi, Claudia Voena, Alberto Zaniboni, Claudio Bordignon et Paolo Corradini. « Nonmyeloablative conditioning followed by hematopoietic cell allografting and donor lymphocyte infusions for patients with metastatic renal and breast cancer ». Blood 99, no 11 (1 juin 2002) : 4234–36. http://dx.doi.org/10.1182/blood.v99.11.4234.
Texte intégralWagner, Anna-Margaretha, Konstantin Beier, Elli Christen, Georg A. Holländer et Werner Krenger. « Leydig cell injury as a consequence of an acute graft-versus-host reaction ». Blood 105, no 7 (1 avril 2005) : 2988–90. http://dx.doi.org/10.1182/blood-2004-07-2646.
Texte intégralThèses sur le sujet "INTERFERON-GAMMA ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION GVHD"
MORELLO, Enrico. « IFN-γ induced by PHA stimulation as new marker for GvHD prediction in patients undergoing allogeneic hematopoietic stem cell transplantation (alloHSCT) ». Doctoral thesis, 2011. http://hdl.handle.net/11562/350426.
Texte intégralIntroduction GVHD is associated with a high morbidity and mortality in alloSCT patients. An early diagnosis of GVHD could reduce this adverse impact on the outcome of alloSCT. The effect of Th1 cytokine IFN-γ is crucial in the pathogenesis of GVHD and, as expected, higher protein levels are reported in the serum of patients with active chronic GVHD. Aims and Methods Our hypotesis is that the monitoring of IFN-γ basal levels as well as IFN-γ induced by mitogen stimulation in the blood samples of patients after alloSCT could help the management and the prediction of GVHD. A recent ELISA based test (QuantiFERON®-CMV) could measure specific (anti-CMV) and aspecific production of IFN-γ in whole blood. The aim of this study is to assess the reliability of the positive control of the QuantiFERON®-CMV kit as new marker for GVHD early diagnosis during immune system reconstitution after bone marrow transplantation. Methods: QuantiFERON®‑CMV is an in vitro diagnostic test that use an antigenic human cytomegalovirus proteins (CMV) peptide cocktail to stimulate cells from whole blood and is used after alloSCT to monitor the occurrence of CMV infection. The mitogen-stimulated (PHA) plasma sample is used as a positive control for each specimen tested. Detection of interferon-γ (IFN-γ) by ELISA is used to identify responses. In order to assess the association between PHA stimulation IFN-γ production and GVHD, we decided to consider 3 different positivity of the test: 1) 0,5 IU/mL as defined by manufacturer, 2) 9 IU/mL as experimentally defined by the median of the observations in our preliminary data set. 3) 5 IU/mL as defined by the median of the values of the prospective study. GVHD extension was defined by Seattle criteria and/or the number of involved sites. A prospective study has been designed in order to confirm these data. Thirty-six patients were prospectively monitored after transplant with QuantiFERON®‑CMV according the following timepoints: every 2-3 weeks until +180d since transplantation, every month until +365d. Lymphocyte subpopulations +28, +56, +84, every month thereafter. Events (acute GVHD, chronic GVHD, relapse, death are registered in the database and matched with the production of PHA induced INF-y; when GVHD was suspected a biopsy of the target organ was recommended. A two step cox regression model for time dependent variables was implemented in order to define risk factors for cGvHD. Results PHA-induced INF-Y increase in the first three months after alloHSCT was independently associated with cGvHD at the multivariate analysis (p= 0.021, 0.015, 0.027 respectively) together with recipient sex (female), age, stem cell source, GvHD prophylaxis and infections. The sensitivity of the test was 97% at the cutoff 1 (0.5 IU/mL). The reduction of PHA-induced INF-Y was detected in all patients treated for a cGvHD but one who did not respond to immune-suppression. Conclusions PHA-induced INF-Y is a reliable biomarker of cGvHD and could help the physician in the management of cGvHD treatment. Further studies are needed in order to better define subsets of patients who could benefit from this test.